Lorenz Kadletz1, Stefan Grasl1, Christos Perisanidis2, Matthäus C Grasl1, Boban M Erovic3. 1. Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. 2. Department of Maxillofacial Surgery, University of Athens, Athens, Greece. 3. Institute of Head and Neck Surgery, Evangelical Hospital, Vienna, Austria. b.erovic@ekhwien.at.
Abstract
PURPOSE: Recently, there has been an increase in the number of reported Warthin's tumors, but few risk factors have been described for this benign tumor. Yet, smoking is the only evidently identified risk factor. Obesity and the metabolic syndrome are causally linked to or a risk factor for a variety of diseases. Therefore, we analyzed whether metabolic syndrome, including obesity, might influence the incidence of Warthin's tumors. METHODS: In this retrospective study, we evaluated 197 patients with Warthin's tumor. We assessed the tumor size, the body mass index (BMI), comorbidities related to the metabolic syndrome, and cigarette and alcohol consumption. Additionally, we evaluated several blood parameters and their influence. RESULTS: Warthin's tumor patients had a significantly higher BMI in comparison to patients with other benign parotid gland tumors (29.1 versus 26.2, p < 0.0001). The rate of metabolic syndrome-associated comorbidities was higher in Warthin's tumor patients (62.4% versus 35.2%, p < 0.0001). CONCLUSION: Our results might be the first step to recognize obesity and its consequences as a co-driver in the formation of Warthin's tumors. Nevertheless, further studies are requested to validate our results and to answer the question whether obesity or the metabolic syndrome are integrally linked to Warthin's tumors.
PURPOSE: Recently, there has been an increase in the number of reported Warthin's tumors, but few risk factors have been described for this benign tumor. Yet, smoking is the only evidently identified risk factor. Obesity and the metabolic syndrome are causally linked to or a risk factor for a variety of diseases. Therefore, we analyzed whether metabolic syndrome, including obesity, might influence the incidence of Warthin's tumors. METHODS: In this retrospective study, we evaluated 197 patients with Warthin's tumor. We assessed the tumor size, the body mass index (BMI), comorbidities related to the metabolic syndrome, and cigarette and alcohol consumption. Additionally, we evaluated several blood parameters and their influence. RESULTS:Warthin's tumorpatients had a significantly higher BMI in comparison to patients with other benign parotid gland tumors (29.1 versus 26.2, p < 0.0001). The rate of metabolic syndrome-associated comorbidities was higher in Warthin's tumorpatients (62.4% versus 35.2%, p < 0.0001). CONCLUSION: Our results might be the first step to recognize obesity and its consequences as a co-driver in the formation of Warthin's tumors. Nevertheless, further studies are requested to validate our results and to answer the question whether obesity or the metabolic syndrome are integrally linked to Warthin's tumors.
Authors: Miquel Quer; Juan C Hernandez-Prera; Carl E Silver; Maria Casasayas; Ricard Simo; Vincent Vander Poorten; Orlando Guntinas-Lichius; Patrick J Bradley; Wai Tong-Ng; Juan P Rodrigo; Antti A Mäkitie; Alessandra Rinaldo; Luiz P Kowalski; Alvaro Sanabria; Remco de Bree; Robert P Takes; Fernando López; Kerry D Olsen; Ashok R Shaha; Alfio Ferlito Journal: Diagnostics (Basel) Date: 2021-08-13
Authors: Adnan S Hussaini; Navin R Prasad; Edina Paal; Eshetu A Tefera; Sonya Malekzadeh; Jessica H Maxwell Journal: World J Otorhinolaryngol Head Neck Surg Date: 2020-07-08